ARTICLE | Company News
XTL, Weizmann Institute of Science deal
January 20, 2014 8:00 AM UTC
Yeda Research and Development Co. Ltd., the institute's technology transfer company, granted XTL exclusive, worldwide rights to hCDR1, a CDR1-based peptide derived from a human anti-DNA antibody in d...